Answers are grounded in this paper and cite their sources.
Histamine H2-receptor antagonists (H2RAs) are widely used drugs which can induce immediate and delayed hypersensitivity reactions (HSRs) including anaphylaxis, urticaria, contact dermatitis, and severe cutaneous adverse reactions. The available evidence is limited by the fact that most data come from case reports and by the absence of large-scale studies. Furthermore, the reported cases are mostly linked to ranitidine, which has been withdrawn from the global market. Consequently, the pathogenesis of these reactions is unclear, resulting in significant clinical challenges. Limited data suggest the usefulness of skin tests (STs) in patients with suspected HSRs to H2RA, but optimal STs concentrations have yet to be established. The same applies to drug provocation tests (DPTs) protocols, which are not standardized. Therefore, the authors recommend taking a step-by-step diagnostic approach. Clinicians are advised to establish non-irritative STs concentrations by testing healthy control subjects. In patients with negative skin test results, supervised DPTs are recommended to confirm tolerance or identify safe alternatives. As cross-reactivity among H2RAs is inconsistent, alternative H2RAs should only be selected following a complete allergological work-up. Addressing these gaps is essential for the safe management of patients, particularly in the light of the recent global re-licensing of reformulated H2RAs.
No takes yet. Share an insight, caveat, or question.
Bavbek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: